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The interaction of drugs with DNA is an important aspect in pharmacology. In recent years, many important technological ad-
vances have been made to develop new techniques to monitor biorecognition and biointeraction on solid devices. The interaction
between DNA and drugs can cause chemical and conformational modiﬁcations and, thus, variation of the electrochemical prop-
erties of nucleobases. The propensity of a given compound to interact with DNA is measured as a function of the decrease of
guanine oxidation signal on a DNA electrochemical biosensor. Covalent binding at N7 of guanine, electrostatic interactions, and
intercalation are the events that this kind of biosensor can detect. In this context, the interaction between a panel of antitumoral
Pt-, Ru-, and Ti-based metallodrugs with DNA immobilized on screen-printed electrodes has been studied. The DNA biosensors
are used for semiquantitative evaluation of the analogous interaction occurring in the biological environment.
Copyright © 2007 Mauro Ravera et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
Chemotherapy is an important weapon for combating can-
cers. Numerous compounds have been developed as poten-
tial candidates for anticancer drugs, but only a handful of
t h e mh a v eb e c o m ee ﬀective in clinical protocols. The need
of developing new drugs in order to eﬀectively treat various
forms of cancer is widely recognized. The development of
new drugs requires that the underlying mechanism of action
at the cellular and molecular levels has been completely un-
derstood.
The potential targets for anticancer drugs are essentially
four: nucleic acids, speciﬁc enzymes, microtubules, and hor-
mone/growth factor receptors. When nucleic acids are the
target, the DNA damage causes cell death (cytotoxic and
genotoxic drugs).
There are several mechanisms by which drugs can bind
DNA [1], the most well understood being alkylation of nu-
cleophilic sites within the double helix. Most clinically ef-
fective alkylating agents have two moieties capable of de-
veloping transient carbocations that bind covalently to the
electron-rich sites on DNA such as the N7 position of gua-
nine (electrophilic agents). The cross-linking of the two
strands of DNA produced by the bifunctional alkylating
agents prevents the use of that DNA as a template for further
DNA and RNA synthesis leading to inhibition of replication
and transcription and, then, to cell death. A large number of
chemical compounds are alkylating agents under physiologic
conditions, and a variety of such compounds have exhibited
antitumor activity. To this category belong nitrogen mus-
tards(mechlorethamine,theoriginal“nitrogenmustard,”cy-
clophosphamide, ifosfamide, melphalan, and chlorambucil),
aziridines and epoxides (thiotepa, mitomycin C, and diaz-
iquone), alkyl sulfonates (like busulfan and its analogues),
nitrosoureas (carmustine, lomustine, and semustine, above
all), triazenes, hydrazines, and related compounds. More-
over, also cisplatin and its congeners are traditionally, albeit
improperly, considered alkylating drugs.
A second mechanism of drug binding to nucleic acids is
intercalation, that is, the insertion of a planar (generally aro-
matic) ring molecule between two adjacent nucleotides of
DNA. This mechanism is characteristic of many antitumor
antibiotics, such as daunorubicin and doxorubicin. The an-
tibiotic molecule is noncovalently, although ﬁrmly, bound to
DNA and distorts the shape of the double helix resulting in
inhibition of DNA replication and RNA transcription.
Finally, a third mechanism of DNA damage is illus-
trated by bleomycins. These glycopeptides intercalate2 Bioinorganic Chemistry and Applications
between guanine-cytosine base pairs of DNA. The end of the
peptide binds Fe(II), able to catalyze the reduction of molec-
ular oxygen to superoxide or hydroxyl radicals, that produce
DNA strand scission by oxidative stress [2].
Due to the stringent relationship between DNA-drug in-
teraction and potential antitumor eﬀect, molecular recogni-
tion of nucleic acids by low molecular weight compounds is
an area of fundamental interest. A detailed understanding of
the interaction of small molecules with DNA is very impor-
tant in pharmacology.
In this context, cisplatin (cis-diamminedichloroplati-
num(II), [Pt(NH3)2Cl2]) probably represents a milestone in
the antitumor chemotherapy. The activity of cisplatin was
serendipitously discovered in 1969 by Rosenberg and col-
leagueswhilestudyingtheeﬀectsofelectriccurrentonbacte-
rial growth. Cisplatin entered clinical trials in the early 1970s
and was found to have signiﬁcant antitumor activity against
testicular, ovarian, bladder, and head and neck cancer. Be-
cause of the nephro- and neuro-toxicity of cisplatin, there
havebeenintensiveeﬀortstodeviseanalogueswithsimilaror
improved pharmacological characteristics. Carboplatin, cis-
diammine-(1,1-cyclobutanedicarboxylato)platinum(II) (ap-
proved worldwide in 1992), shows an antitumor activ-
ity similar to that of cisplatin, but with reduced sys-
temic toxicity (better therapeutic index), while oxaliplatin
(1R,2R-diaminocyclohexane)oxalatoplatinum(II) (approved
for clinical use worldwide in 2003) is eﬀective against col-
orectal tumors, which are nonsensitive to cisplatin. The
consciousness that cisplatin readily reacts with DNA, and
that this reaction is crucial in the antitumor activity, fo-
cused a great attention in the ﬁeld of the interaction
between metal complexes and biomolecules. Today, forty
years after the discovery of the properties of cisplatin,
there is no other metal, that is, better understood in its
reactivity toward DNA than platinum. Moreover, despite
the enormous amount of other metal complexes tested,
cancer chemotherapy using metallopharmaceuticals is still
largely dominated by platinum compounds [3]. The ex-
ploration of nonplatinum metal complexes for use as an-
ticancer agents was initiated in attempts to ﬁnd less toxic
and morespeciﬁc drugs.Inthis framework,some ruthenium
and titanium complexes have oﬀered the most encouraging
results [4]. The imidazolium trans-[tetrachlorodimethyl-
sulfoxideimidazoleruthenate(III)] (NAMI-A, [ImH][trans-
RuCl4(DMSO)Im], Im = imidazole) failed the classical
screens of putative anticancer agents, but prevented the de-
velopment and growth of pulmonary metastases in solid tu-
mors [5–8], and recently has successfully completed Phase
I Clinical Trials [9]. The closely related compound, in-
dazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)]
(KP1019, [IndH][trans-RuCl4Ind2], Ind = indazole) in-
duces apoptosis in colorectal carcinoma cells and it
is currently in Phase I Clinical Trials [10]. Two ti-
tanium compounds [11], namely titanocene dichloride
[TiCl2Cp2][ 12, 13] and budotitane, a β-diketonate deriva-
tive, [cis-diethoxybis(1-phenylbutane-1,3-dionato)titanium
(IV)] [14], reached Phase II and Phase I Clinical Trials in
Germany, respectively. The general mechanism of action of
these nonplatinum compounds is not completely under-
stood yet, but many observations point out that DNA may
not be the primary target of these classes of compounds
[15, 16].
Characterization of DNA-adducts generally requires a
combination of chemical and biological techniques to obtain
structural information and to assess the extent and the na-
ture of speciﬁc type of binding to DNA, in terms of dissocia-
tion constant, stoichiometry, and kinetic constant. Methods
able to evaluate the presence of any interaction and, in some
cases, to calculate the binding parameter can be classiﬁed as
mixture- and separation-based methodology. The mexture-
based type includes UV absorption and ﬂuorescence [17],
nuclear magnetic resonance (NMR, [18]), and Raman spec-
troscopy [19], mass spectrometry (MS, [20]), calorimetry
[21], and surface plasma resonance [22]. The separation-
based methods include dialysis, ultraﬁltration, ultracentrifu-
gation, chromatography (liquid chromatography and thin-
layer chromatography), and electrophoresis (planar and cap-
illaryelectrophoresis[23,24]).Thelasttwoseparationmeth-
ods are generally combined with sensitive detection tech-
niques (hyphenated techniques), such as MS.
Among the physicochemical techniques, there has been
a growing interest in electrochemical investigations. Com-
paredtoothermethods,electrochemicaltechniquesarechar-
acterized by simplicity and reliability and require small
amounts of sample, thus oﬀering advantages over biological
and chemical assays. Since many small molecules exhibit re-
dox activity, electrochemical method should provide a useful
complement to the previously listed methods of investiga-
tion.
The electrochemical method is mainly based on the dif-
ferences in the redox behavior of the nucleic acid-binding
molecules in the absence and presence of DNA—including
the shifts of the formal potential of the redox couple and the
decrease of the peak current resulting from the dramatic de-
crease in the diﬀusion coeﬃcient after association with DNA
(solution electrochemical methods) (see [25]f o rar e c e n tr e -
view).
On the other hand, since the discovery of the electro-
chemical activity of nucleic acids by Paleˇ cek at the end of the
1950s [26], also DNA has been on the focus of the electro-
chemical techniques. The binding of drugs to DNA has been
described by means of the variation of the oxidation peak
current of the electroactive nucleobases, such as guanine and
adenine, in the presence of the interacting species.
According to a recent IUPAC document [27], a biosen-
sor is deﬁned as a speciﬁc type of chemical sensor compris-
ing a biological recognition element and a physicochemical
transducer. The biological element is capable of recognizing
the presence, activity, or concentration of a speciﬁc analyte
in solution. The recognition may be either a binding pro-
cess (aﬃnity ligand-based biosensor, when the recognition
element is, e.g., an antibody, a DNA segment, or a cell recep-
tor)orabiocatalyticreaction(enzyme-basedbiosensor).The
interaction of the recognition element with a target analyte
resultsinameasurablechangeinagivenproperty.Thetrans-
ducer converts the change in solution property into a quan-
tiﬁable signal. The mode of transduction may employ sev-
eral techniques, including electrochemical, optical, and massMauro Ravera et al. 3
or heat measurements. In our case, the electrochemical DNA
biosensor consists of a nucleic acid recognition layer, that is,
immobilized over an electrochemical transducer [28]. The
signal transducer monitors the change that has occurred as
a consequence of the binding, converting this into an elec-
tronic signal [29]. Observing the pre- and postelectrochemi-
cal signals of DNA-drug interaction provides good evidence
fortheevent.Thereproducibilityoftheexperimentisstrictly
related to the history of the electrode surface. In particular,
the preparation of the electrode surface inﬂuences the ﬁnal
response.Forthisreason,theuseofdisposable,low-costelec-
trode characterized by high reproducibility overcomes the
problem, as far as a new, fresh surface is used in each exper-
iment. Various planar technologies are employed for devel-
oping solid-state sensors having the above-said characteris-
tics [30]. Screen printing is especially suitable due to its sim-
plicity, low-cost, high reproducibility, and eﬃciency in large-
scale production. This technology enables the deposition of
a thick layer of conductive ink on inexpensive substrates and
allows precise pattern control.
Althoughsystematicresearchinthisﬁeldstartedrecently,
several seminal review articles have already been focused on
this topic [31–44].
The use of DNA-based biosensors is not limited to the
studyofinteractionbetweendrugsandDNA,butmanyother
applications have been reported. On one hand, DNA- iosen-
sors have been used to test water, food, soil, ﬁsh bile [45],
and plant samples for the presence of mutagenic pollutants
with binding aﬃnities for the structure of DNA [33, 45–54];
on the other hand, DNA-based aﬃnity biosensors have been
used to detect speciﬁc oligonucleotide sequences in order to
ﬁnd the presence of genes (or mutant genes) associated with
particular human diseases [55]. Both aspects are beyond the
focus of this paper and will not be discussed further.
However, speciﬁc oligonucleotide sequences may be re-
lated to the protective cell mechanisms that act against an-
ticancer drugs (drug resistance). One of the main obsta-
cles in the use of metallodrugs in clinical treatment is the
development of resistance. In the case of platinum drugs,
many mechanisms have been proposed to explain resistance,
suggesting that this phenomenon is multifactorial: decrease
of intracellular drug accumulation, faster repair of DNA
adducts, and increased activity of intracellular pathways of
thiol production, in particular glutathione, metallothionein,
and thioredoxin, known to be involved in the detoxiﬁca-
tion of metals. For these reasons, any information on DNA-
binding modes, recognition, and repair of DNA damage may
be helpful not only to understand the molecular basis of the
repair mechanisms, but also to develop new classes of com-
pounds with improved pharmacological properties [56, 57].
2. DISCUSSION
2.1. Preparationofthescreen-printed
electrodes(SPEs)
Screen printing is a technique conventionally used in the
graphics industry, in the production of circuit boards, or in
printing t-shirt designs. When inexpensive, easily mass pro-
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Figure 1: Scan of a screen-printed cell used as electrochemical
transducerforthebiosensorsconstruction,containingthesilverref-
erence electrode (left), the graphite working (centre), and auxiliary
electrodes (right).
duced, and, therefore, disposable electrodes for the devel-
opment of electrochemical biosensors are required, screen-
printingisaviableproductionmethod.Singleusesensorsas-
sure avoidance of contamination between samples and con-
stantsensitivityofthediﬀerentprintedsensors.Awiderange
of diﬀerent inks (carbon or noble metals-based) and base
materials (ceramics or plastic base materials) can be com-
bined to produce electrode systems to suit speciﬁc applica-
tions.
The planar SPEs used in our laboratories have a three-
electrode conﬁguration (Figure 1). They are printed by using
inks consisting in ﬁnely divided particles of diﬀerent materi-
als in a blend of thermoplastic resins (silver ink for the ref-
erence electrode, graphite ink for working and counter elec-
trodes,whiletitaniumdioxideinkwasusedforinsulatingthe
electrodes).
The sensors were produced in sheets of 80 electrodes. To
facilitate handling, the screen-printed electrochemical cells
were stuck on a rigid polycarbonate-based support. Each
(disposable) electrode can be easily cut by scissors and ﬁts
a standard electrical connector [30, 58, 59].
2.2. Preparationofthebiosensor
As already mentioned in the Introduction, a biosensor is de-
ﬁned as an analytical device, which is capable of providing
quantitative or semiquantitative analytical information us-
ing a biological recognition element either integrated within
or intimately associated with a physicochemical transducer
[27]. In our case, the transducer is the SPE while the oxida-
tion peak of guanines is used as the transduction signal for
recognize DNA interactions.
The preparation and the following measurement of the
interaction at the DNA-modiﬁed SPEs include four steps
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(1) Electrode activation: a (mild) surface conditioning step
is necessary to oxidize the graphite impurities and to
obtain a more hydrophilic surface to favor DNA im-
mobilization (+1.6V versus Ag-pseudoreference for
120seconds and +1.8V for 60seconds in 0.25M ac-
etate buﬀer, containing 10mM KCl, pH 4.75, under
stirred conditions).
(2) DNA immobilization: in this step DNA is electrochem-
ically accumulated and adsorbed onto the electrode
surface by applying a positive potential able to at-
tract negative charged groups of DNA (activated SPE
is dipped in a solution of 50ppm calf thymus ds-DNA
in 0.25M acetate buﬀer with 10mM KCl, applying a
potential of +0.5V versus Ag-SPE for 5minutes, un-
der stirred conditions).
(3) Blank or sample interaction: in this step, the response
of the guanine before (reference signal) or after inter-
action is evaluated (the DNA-modiﬁed SPE is dipped
for 2minutes in a solution containing the interacting
molecule dissolved in a suitable buﬀer/saline solution
or in the same buﬀer saline solution without any ana-
lyte, to obtain the reference).
(4) Measurement: a square wave voltammetric (SWV)
scan is carried out to evaluate the oxidation of gua-
nine residues on the electrode surface (the height of
the guanine peak at +0.95V versus Ag-SPE was mea-
suredin0.25Macetatebuﬀer,containing10mMKCl).
The four-step protocol is the result of a series of experi-
ments aimed to optimize the ﬁnal response, in terms of peak
height and reproducibility of the signal [50, 60]. The results
showedanincreaseofthesensitivityincreasingDNAconcen-
tration (until a saturation phenomenon occurred) and the
immobilization time (similar results were obtained by other
authors. See [61]). The 50ppm ds-DNA concentration and
an immobilization time of 5minutes (step 2) were chosen as
the best compromise for further experiments.
DNA biosensor performances were strongly inﬂuenced
by the physical properties of DNA (i.e., purity, average chain
length, presence of ss-DNA) [48]. Moreover, the solution
wheretheﬁnalmeasurementisperformedinﬂuencesthesig-
nal aspect: the acetate buﬀer gives the best results [48, 50],
and this choice was reported also by other authors [62].
We usually estimate the DNA modiﬁcation due to the
interaction with the analyte with the value of the percent-
age of signal decrease (S%). This value is the ratio of the
guanine peak height after the interaction of the DNA ad-
sorbed onto the SPE with the analyte (Ssample) and the gua-
nine peak height of the DNA in the buﬀer solution without
drug (Sblank), S% = (Ssample/Sblank) × 100. A typical voltam-
mogram is shown in Figure 2.
ItmustbenotedthatthetwocurvesofFigure 2havebeen
obtainedfromtwodiﬀerentSPEs.Infact,onlyoneSWVscan
is allowed on each biosensor. If a second SWV is performed,
no peak can be observed because of the complete oxidation
of the guanine of the immobilized DNA [48]. For this rea-
son, the ﬁnal S% values are expressed as a mean of (at least)
three independent measurements. With this procedure, the
“memory eﬀect”betweenonesampleandanotherisavoided.
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Figure 2: Redox behavior of guanine (G,+ 0 .95V versus Ag-SPE)
and adenine (A,+ 1 .25V versus Ag-SPE) bases after an SWV scan
carried out with graphite SPE (a baseline correction on the original
signals was performed). Note that the signal of DNA alone (solid
line) and the decrease of the DNA peaks after the interaction with a
general compound able to interact with DNA (dashed line).
The phenomenon referred to as “electrode fouling,” which is
one of the main drawbacks of the electrochemical sensors, is
overcome and no calibration is required. Furthermore, the
reproducibility of the guanine peak height, calculated over
three or more scans on diﬀerent electrodes is very high, and
the standard deviation was estimated to be less than 10%.
It is also possible to study the adenine oxidation peak,
b u ti nt h i sc a s el e s sr e p r o d u c i b l es i g n a l sa r eo b t a i n e d( s e ee r -
ror bars in Figure 2)[ 54]. Moreover, this peak is sometimes
obscured by the solvent discharge.
Covalent binding with one or both grooves of the double
helix, hydrogen and/or van der Waals bonds and intercala-
tion of planar condensed aromatic ring systems between ad-
jacent base pairs (π-stacking) are the perturbations that the
electrochemical DNA biosensor can detect [63].
2.3. Platinumcomplexes[64,65]
Cisplatin, 1 (Figure 3), is administered intravenously for
clinical use. In the extracellular environment, the plat-
inum compound experiences high chloride concentration
(∼100mM) and does not undergo appreciable hydrolysis.
When cisplatin passes the cell membrane, the reduced in-
tracellular chloride concentration (∼5–10mM) allows the
chloro ligands to be replaced in a stepwise manner by
water molecules to form cis-[Pt(H2O)(NH3)2Cl]+ and cis-
[Pt(H2O)2(NH3)2]2+ [66]. It is generally accepted that these
two ions are much more reactive than cisplatin and, there-
fore, react with N-donor ligands, such as DNA nucleobases
(the preferred target on DNA is recognized as the guanines
having the highest electron density of all four nucleobases),
leading to the bending of the DNA structure by 35–40◦ [67–
69]. This key reaction is responsible for the anticancer ef-
fect of cisplatin which is able to induce apoptosis/necrosis of
the cancer cell [70]. Carboplatin, 2, undergoes much slowerMauro Ravera et al. 5
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Figure 3: Sketch of the Pt(II) complexes investigated.
hydrolysis than cisplatin. Since the DNA reactions are pri-
marily limited by the hydrolytic pathways, the reaction be-
tween carboplatin and DNA is extremely slow under physi-
ological conditions. For example, the half life of carboplatin
reaction with DNA is estimated to be several days [71].
The behavior of these two complexes was compared with
that of [Pt(bpy)(py)2][PF6]2, 3 (bpy = bipyridyl, py = pyri-
dine). This complex lacks appropriate leaving groups, so that
3 is devoid of any alkylating properties, but is able to interca-
late DNA [72].
Figure 4 shows the trend of S% values resulting from the
interaction between DNA biosensor and a 0.1mM solution
of 1 in 5mM (intracellular conditions) and 100mM (extra-
cellular conditions) NaCl, respectively. As expected, the be-
havior of 1 strictly depends on the concentration of the NaCl
and on the aging time of the solution: high concentrations
of chlorides inhibit the aquation of cisplatin and, hence, its
interaction with DNA.
As far as 1 becomes, after hydrolysis, doubly positive
charged species, we have checked whether a simple long-
range electrostatic interaction in lieu of an eﬀective coor-
dination to DNA is able to aﬀect the oxidation signal of
guanine. For this purpose, we have tested the interaction
between the biosensor and solutions containing divalent
cations Zn(II) and Cu(II). For both solutions, no variation
in the guanine signal was observed (S% = 100%).
Figure 5 shows the S% values resulting from increasing
concentrations of metal complexes 1–3 in 0.25M phosphate
buﬀer (PB, pH = 7.4), containing 5mM NaCl (intracellular
conditions).
The interaction increases in a dose-dependent manner,
and is stronger for 1 and softer for 2.C o m p o u n d3 shows an
initial strong interaction, overimposable to that of 1,b u ta
minor one at higher concentrations, probably because of the
saturation of the intercalating sites on DNA.
Figure 6 compares the behavior of the three metal com-
plexes in identical experimental conditions (in particular at
the same concentration) when the solution aging time is var-
ied. As expected, a stronger eﬀect of solution aging time on
S%i so b s e r v e df o r1, while, in the case of 3,h y d r o l y s i si sn o t
required.Infact,thiscomplexdoesnotneedtodissociateany
ancillary ligand to exert its activity.
Compounds 1 and 2 produce the same electrophilic
agent upon hydrolysis, namely [Pt(H2O)2(NH3)2]2+,n e v e r -
theless, Figures 5 and 6 reveal that the interaction of carbo-
platin is much lower than that of cisplatin because of the dif-
ferent rate of hydrolysis (t1/2 in chloride-free phosphate at
37◦Ci sa b o u t4 5 0h o u r sf o r2 [71] compared with 2hours
for cisplatin [73]).
In the case of 2, the rate of hydrolysis, and hence
the interaction with DNA, is increased in the presence
of chlorides. In fact, an exchange between the 1,1-cyclob-
utanedicarboxylato ligand and chlorides in solution is able
to transform 2 in 1 [74] that, in turn, undergoes quick
activation by aquation. This eﬀect is negligible in the
presence of weaker Lewis bases, for instance perchlorates
(Figure 7). The exchange reaction is time-dependent as ob-
served in both in 2 and in its malonato-analogue (cis-diam-
minomalonatoplatinum, [Pt(NH3)2(malonato)], 4), and in-
c r e a s e sw i t h[ C l −]( Figure 8).6 Bioinorganic Chemistry and Applications
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Figure 4: S% versus solution aging time for 0.1mM solution of 1
in unbuﬀered (pH = 7.4) 5mM NaCl (circles), and 100mM NaCl
(squares) solutions, respectively.
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Figure 5: S% resulting from increasing concentrations of metal
complexes in 0.25M PB (pH = 7.4) and 5mM NaCl (interaction
time = 2minutes).
The biosensor may also be used to diﬀerentiate the in-
tercalating from the covalent interactions. In fact, by using
the same experimental procedures previously described, it is
possible to adsorb single-stranded DNA onto the SPE [48].
Similar concentrations of compound 3 gave lower S%v a l u e s
(i.e., higher interaction) on the ds-DNA- versus the ss-DNA-
based sensor (S% = 65±3v e r s u s9 2±3, resp.), enforcing the
experimental data that identify this complex as an intercala-
tor in lieu of a coordinating agent.
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Figure 6: S% versus solution aging time for 0.5mM solution of the
metal complexes 1–3 in 0.25M PB (pH = 7.4) and 5mM NaCl.
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Figure 7: S% obtained with diﬀerent concentrations of carboplatin
in 100mM NaCl or 100mM NaClO4,r e s p e c t i v e l y .
2.4. Rutheniumcomplexes:NAMI-A
The complex NAMI-A, (H2Im)[trans-Ru(III)Cl4(DMSO)-
(Im)], is a pseudo-octahedral complex with four equatorial
chloride ligands and the heterocyclic bases and DMSO as ax-
ial ligands (Figure 9).
The complex loses its chloride ligands and transforms
into the corresponding, more reactive, aquated species [4]
able to bind irreversibly to DNA, albeit this binding is weakerMauro Ravera et al. 7
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Figure 8: S% versus solution aging time for 0.5mM solution of 4
in 5 or 100mM NaCl, respectively, (previously unpublished data).
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Figure 9: Sketch of the non-Pt(II) complexes investigated.
than for similar platinum complexes [75]. In fact, Gallori
et al. showed that NAMI-A interacts with DNA at concen-
trations signiﬁcantly higher than those at which cisplatin
produces similar eﬀects [76]. On the other hand, tight bind-
ing of NAMI-A to proteins has been described [64, 77, 78]
anditislikelytoconceivethatthemechanismunderlyingthe
antimetastatic activities of NAMI-A does not involve DNA
bindingasthemostsigniﬁcantprocess,but,perhapstheinhi-
bitionofthematrixmetallo-proteinasesMMP-2andMMP-9
[8].
Also in the case of NAMI-A, S% value decreases as con-
centration increases (Figure 9), but the concentration of the
supporting electrolyte plays minor roles (Figures 9 and 10).
In fact, NaCl, that should exert mass eﬀect, and NaClO4, that
produces the noncoordinating perchlorate anion, gave sim-
ilar results (Figure 9)[ 64]. Indeed, it is known in literature
that chlorides have a minor eﬀect over NAMI-A aquation
[79]. NAMI-A shows higher S%v a l u e si nc o m p a r i s o nw i t h
1,especiallyatlowchlorideconcentration.Theseexperimen-
tal data further reinforce the hypothesis that DNA is not the
preferential targets of NAMI-A.
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Figure 10: S% versus [NAMI-A] in 5mM NaCl (squares) and
5mMN aClO 4 (triangles) solutions, respectively.
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lutions, respectively, compared to the trend of the same concentra-
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2.5. Titaniumcomplexes
Unlike the very well-studied platinum complexes, interac-
tions of Ti complexes with DNA are poorly understood. It
seems that titanocene dichloride TiCp2Cl2 (Figure 11)i sa b l e
to interact with transferrin, the protein associated with iron
transport. In this form, titanium active species could cross
the cell membrane, but the nature of the actual cytotoxic
species remains unknown [15].
In literature, there are conﬂicting results about whether
titanocene dichloride binds DNA or not. Some reports have8 Bioinorganic Chemistry and Applications
suggested that TiCp2Cl2 does not bind nucleotides and
oligonucleotides at physiological pH [80–82], but there is ex-
perimental evidences of titanium being accumulated in the
cellular nucleic acid-rich regions, particularly in the chro-
matin [83]. Recently, it has been shown that TiCp2Cl2 inter-
actsweaklywithnucleotidesatneutralpHthroughthephos-
p h o e s t e r sm o s tp r o b a b l ya sb a r eT i ( I V )s p e c i e s[ 84].
These conﬂicting results about titanocene dichloride
binds DNA prompted us to test if the biosensor were able
to give some information about the degree of interaction.
Figures 12 and 13 show, unequivocally, that TiCp2Cl2
has a lower degree of interaction with DNA biosensor than
cisplatin [65]. The trend of S% with solution aging time
is almost constant. These two points ﬁt with the literature
data showing that the hydrolysis of TiCp2Cl2 proceeds much
faster than cisplatin: the half-life of the ﬁrst aquation of
chloride ligand is too fast to be measured and the second
aquation step has a t1/2 ≈ 50minutes [80]. Therefore, we
expect that both the active species [TiCp2(H2O)Cl]+ and
[TiCp2(H2O)2]2+ are present in solution just at the begin-
ning of the experiment. If we accept that the DNA binding
occurs at the phosphate groups level, it is evident that an
ionic interaction between Ti cation and external phosphate
backbone produces a minor eﬀect on the oxidation of G with
respect to the direct coordination of N7.
3. CONCLUDING REMARKS
In the ﬁeld of environmental sciences it has been demon-
strated the good relationship between genotoxicity of a sam-
ple (measured by speciﬁc assays like Toxalert) and the pres-
ence of substances with high aﬃnity for DNA (measured by
the DNA biosensor) [48, 50, 51], but the use of biosensors in
pharmacokinetic studies deserves some caution.
It is generally accepted that a direct relationship between
cytotoxicity and DNA-bound Pt exists [85–87], but there are
also many factors that hamper the DNA platination. The
DNA biosensors do not give an “absolute” measure of the
genotoxic power of a potential drug as it uses DNA free of hi-
stones, not organized in superior structures, and nuclear and
cellular membranes are missing. Furthermore, in a cell-free
system,thecellularthiols(glutathioneandmetallothioneins)
able to intercept the platinum complexes are not present and
other repair mechanisms are missing.
Moreover, the ratio between metal drug and DNA is far
from real pharmacological conditions. In fact, in the case of
Pt drugs, it has been measured that cytotoxicity occurs when
there are around 2–10nmoles of Pt/gD N A[ 88]. Our deter-
minations revealed that about 3 × 10−9 g of DNA coated the
biosensor [65, 89]. This means that the ratio between metal
complex and immobilized DNA is incredibly high and in
these conditions a large number of compounds could inter-
actwithguanine,evenwithoutbeingactiveantitumordrugs.
However, this procedure can be very useful for a rapid
screening of the samples and may be of interest in studying
(i) the possible reaction of the metal complex in solution and
hence the formation of DNA-active or inactive species by re-
action with water or other molecules acting as ligand (i.e.,
chlorides), and (ii) the strength of perturbation caused di-
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Figure 12: S% versus [metal complex] in 0.25M PB/5mM NaCl
solutions of TiCp2Cl2 and 1,r e s p e c t i v e l y .
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Figure 13: S% versus solution aging time for 0.5mM solution of
TiCp2Cl2 in 0.25M PB/5mM NaCl, compared to the trend of the
same concentration of 1.
rectly or through the DNA chain by such metallodrugs on
the electron density of N7-G, that is, the real observable in
such a measurements.
Fortheabovereasons,theDNAbiosensorcouldgiveuse-
ful and quick information and could be integrated in a panel
of tests in order to quickly evaluate and quantiﬁes the aﬃnity
of low-weight molecules with DNA.
ACKNOWLEDGMENTS
Useful discussions were carried out with colleagues within
the framework of the European Cooperation COST D39Mauro Ravera et al. 9
(Metallo-Drug Design and Action) and COST B16 (Mul-
tidrug resistance reversal) actions. The contributions of the
many talented students and coworkers who have contributed
to the work described in this review are acknowledged. This
paper is based on a lecture given by the ﬁrst author at the 9th
International Symposium on Applied Bioinorganic Chem-
istry (ISABC) held in Naples, Italy, on December 4th, 2006.
REFERENCES
[1] G. Bischoﬀ and S. Hoﬀmann, “DNA-binding of drugs used
in medicinal therapies,” Current Medicinal Chemistry, vol. 9,
no. 3, pp. 321–348, 2002.
[ 2 ]L .L .B r u n t o n ,J .S .L a z o ,a n dK .L .P a r k e r ,E d s . ,Goodman &
Gilman’s the Pharmacological Basis of Therapeutics, McGraw-
Hill, New York, NY, USA, 11th edition, 2006.
[3] B. Lippert, Ed., Cisplatin: Chemistry and Biochemistry of a
Leading Anticancer Drug,W i l e y - V C H ,N e wY o r k ,N Y ,U S A ,
1999.
[ 4 ]M .J .C l a r k e ,F .Z h u ,a n dD .R .F r a s c a ,“ N o n - p l a t i n u m
chemotherapeutic metallopharmaceuticals,” Chemical Re-
views, vol. 99, no. 9, pp. 2511–2533, 1999.
[5] G. Sava, I. Capozzi, K. Clerici, G. Gagliardi, E. Alessio, and
G. Mestroni, “Pharmacological control of lung metastases of
solid tumours by a novel ruthenium complex,” Clinical and
Experimental Metastasis, vol. 16, no. 4, pp. 371–379, 1998.
[6] G. Sava, A. Bergamo, S. Zorzet, et al., “Inﬂuence of chemical
stability on the activity of the antimetastasis ruthenium com-
pound NAMI-A,” European Journal of Cancer, vol. 38, no. 3,
pp. 427–435, 2002.
[7] A. Bergamo, R. Gagliardi, V. Scarcia, et al., “In vitro cell cy-
cle arrest, in vivo action on solid metastasizing tumors, and
host toxicity of the antimetastatic drug NAMI-A and cis-
platin,” Journal of Pharmacology and Experimental Therapeu-
tics, vol. 289, no. 1, pp. 559–564, 1999.
[8] G. Sava, S. Zorzet, C. Turrin, et al., “Dual action of NAMI-A
in inhibition of solid tumor metastasis: selective targeting of
metastatic cells and binding to collagen,” Clinical Cancer Re-
search, vol. 9, no. 5, pp. 1898–1905, 2003.
[9] J. M. Rademaker-Lakhai, D. van den Bongard, D. Pluim, J.
H. Beijnen, and J. H. M. Schellens, “A phase I and phar-
macologicalstudywithimidazolium-trans-DMSO-imidazole-
tetrachlororuthenate, a novel ruthenium anticancer agent,”
Clinical Cancer Research, vol. 10, no. 11, pp. 3717–3727, 2004.
[10] S. Kapitza, M. Pongratz, M. A. Jakupec, et al., “Heterocyclic
complexes of ruthenium(III) induce apoptosis in colorectal
carcinoma cells,” Journal of Cancer Research and Clinical On-
cology, vol. 131, no. 2, pp. 101–110, 2005.
[11] F. Caruso and M. Rossi, “Antitumor titanium compounds,”
Mini-Reviews in Medicinal Chemistry, vol. 4, no. 1, pp. 49–60,
2004.
[12] G. L¨ ummen, H. Sperling, H. Luboldt, T. Otto, and H. R¨ ubben,
“Phase II trial of titanocene dichloride in advanced renal-cell
carcinoma,” Cancer Chemotherapy and Pharmacology, vol. 42,
no. 5, pp. 415–417, 1998.
[13] N. Kr¨ o g e r ,U .R .K l e e b e r g ,K .M r o s s ,L .E d l e r ,a n dD .K .H o s s -
feld, “Phase II clinical trial of titanocene dichloride in patients
with metastatic breast cancer,” Onkologie,v o l .2 3 ,n o .1 ,p p .
60–62, 2000.
[14] T. Schilling, K. B. Keppler, M. E. Heim, et al., “Clinical phase
I and pharmacokinetic trial of the new titanium complex bu-
dotitane,” Investigational New Drugs, vol. 13, no. 4, pp. 327–
332, 1995.
[15] M. Guo, H. Sun, H. J. McArdle, L. Gambling, and P. J. Sadler,
“Ti
IV uptake and release by human serum transferrin and
recognition of Ti
IV-transferrin by cancer cells: understanding
the mechanism of action of the anticancer drug titanocene
dichloride,” Biochemistry, vol. 39, no. 33, pp. 10023–10033,
2000.
[16] E. Alessio, G. Mestroni, A. Bergamo, and G. Sava, “Ruthenium
anticancer drugs,” in Metal Complexes in Tumor Diagnosis and
as Anticancer Agents, A. Sigel and H. Sigel, Eds., vol. 42 of
Metal Ions in Biological Systems, chapter 10, pp. 323–351, Mar-
cel Dekker, New York, NY, USA, 2004.
[17] T. C. Jenkins, “Optical absorbance and ﬂuorescence tech-
niques for measuring DNA drug interactions,” in Drug DNA
Interaction Protocols,K .R .F o x ,E d . ,v o l .9 0o fMethods in
Molecular Biology, pp. 195–218, Humana Press, Totowa, NJ,
USA, 1997.
[18] M. S. Searle, “NMR studies of drug-DNA interactions,”
Progress in Nuclear Magnetic Resonance Spectroscopy, vol. 25,
no. 5, pp. 403–480, 1993.
[19] J. M. Benevides, S. A. Overman, and G. J. Thomas Jr., “Ra-
man,polarizedRamanandultravioletresonanceRamanspec-
troscopy of nucleic acids and their complexes,” Journal of Ra-
man Spectroscopy, vol. 36, no. 4, pp. 279–299, 2005.
[20] A. Di Tullio, S. Reale, and F. De Angelis, “Molecular recog-
nition by mass spectrometry,” J o u r n a lo fM a s sS p e c t r o m e t r y ,
vol. 40, no. 7, pp. 845–865, 2005.
[21] H. P. Hopkins, “Calorimetric techniques for studying drug-
DNA interactions,” in Drug DNA Interaction Protocols,K .R .
Fox, Ed., vol. 90 of Methods in Molecular Biology, pp. 259–268,
Humana Press, Totowa, NJ, USA, 1997.
[22] L.-P. Lin, L.-S. Huang, C.-W. Lin, et al., “Determination of
binding constant of DNA-binding drug to target DNA by sur-
face plasmon resonance biosensor technology,” Current Drug
Targets: Immune, Endocrine & Metabolic Disorders, vol. 5,
no. 1, pp. 61–72, 2005.
[23] C. Schou and N. H. H. Heegaard, “Recent applications of
aﬃnity interactions in capillary electrophoresis,” Electrophore-
sis, vol. 27, no. 1, pp. 44–59, 2006.
[24] J. Zavaleta, D. Chinchilla, A. Brown, et al., “Recent develop-
ments in aﬃnity capillary electrophoresis: a review,” Current
Analytical Chemistry, vol. 2, no. 1, pp. 35–42, 2006.
[25] S. Rauf, J. J. Gooding, K. Akhtar, et al., “Electrochemical ap-
proach of anticancer drugs-DNAinteraction,” J o urnalo fPhar -
maceuticalandBiomedicalAnalysis,vol.37,no.2,pp.205–217,
2005.
[26] E. Paleˇ cek, “Oscillographic polarography of highly polymer-
ized deoxyribonucleic acid,” Nature, vol. 188, no. 4751, pp.
656–657, 1960.
[27] D. R. Th´ evenot, K. Toth, R. A. Durst, and G. S. Wilson, “Elec-
trochemical biosensors: recommended deﬁnitions and clas-
siﬁcation,” Biosensors and Bioelectronics, vol. 16, no. 1-2, pp.
121–131, 2001.
[28] F. Lucarelli, G. Marrazza, A. P. F. Turner, and M. Mascini,
“Carbon and gold electrodes as electrochemical transducers
for DNA hybridisation sensors,” Biosensors and Bioelectronics,
vol. 19, no. 6, pp. 515–530, 2004.
[29] J. J. Gooding, “Electrochemical DNA hybridization biosen-
sors,” Electroanalysis, vol. 14, no. 17, pp. 1149–1156, 2002.
[30] S. Laschi and M. Mascini, “Planar electrochemical sensors
for biomedical applications,” Medical Engineering and Physics,
vol. 28, no. 10, pp. 934–943, 2006.
[31] S. Palanti, G. Marrazza, and M. Mascini, “Electrochemical
DNAprobes,”AnalyticalLetters,vol.29,no.13,pp.2309–2331,
1996.10 Bioinorganic Chemistry and Applications
[32] E. Paleˇ cek, “From polarography of DNA to microanalysis with
nucleic acid-modiﬁed electrodes,” Electroanalysis, vol. 8, no. 1,
pp. 7–14, 1996.
[33] J. Wang, G. Rivas, X. Cai, et al., “DNA electrochemical biosen-
sorsforenvironmentalmonitoring.areview,”AnalyticaChim-
ica Acta, vol. 347, no. 1-2, pp. 1–8, 1997.
[34] J. Zhai, H. Cui, and R. Yang, “DNA based biosensors,” Biotech-
nology Advances, vol. 15, no. 1, pp. 43–58, 1997.
[35] E. Paleˇ cek, M. Fojta, M. Tomschik, and J. Wang, “Electro-
chemical biosensors for DNA hybridization and DNA dam-
age,” Biosensors and Bioelectronics, vol. 13, no. 6, pp. 621–628,
1998.
[36] E. Paleˇ cek, “Past, present and future of nucleic acids electro-
chemistry,” Talanta, vol. 56, no. 5, pp. 809–819, 2002.
[37] A. Erdem and M. Ozsoz, “Electrochemical DNA biosensors
b a s e do nD N A - d r u gi n t e r a c t i o n s , ”Electroanalysis, vol. 14,
no. 14, pp. 965–974, 2002.
[38] J.Wang,“Real-timeelectrochemicalmonitoring:towardgreen
analytical chemistry,” Accounts of Chemical Research, vol. 35,
no. 9, pp. 811–816, 2002.
[39] M. Dequaire and A. Heller, “Screen printing of nucleic acid
detecting carbon electrodes,” Analytical Chemistry, vol. 74,
no. 17, pp. 4370–4377, 2002.
[40] G. A. Rivas, M. L. Pedano, and N. F. Ferreyra, “Electrochemi-
cal biosensors for sequence-speciﬁc DNA detection,” Analyti-
cal Letters, vol. 38, no. 15, pp. 2653–2703, 2005.
[41] M. Mehrvar and M. Abdi, “Recent developments, characteris-
tics, and potential applications of electrochemical biosensors,”
Analytical Sciences, vol. 20, no. 8, pp. 1113–1126, 2004.
[ 4 2 ]J .P .H a r t ,A .C r e w ,E .C r o u c h ,K .C .H o n e y c h u r c h ,a n dR .
M. Pemberton, “Some recent designs and developments of
screen-printed carbon electrochemical sensors/biosensors for
biomedical, environmental, and industrial analyses,” Analyti-
cal Letters, vol. 37, no. 5, pp. 789–830, 2005.
[43] H.JuandH.Zhao,“ElectrochemicalbiosensorsforDNAanal-
ysis,” Frontiers in Bioscience, vol. 10, no. 1, pp. 37–46, 2005.
[44] K. Kerman, M. Kobayashi, and E. Tamiya, “Recent trends
in electrochemical DNA biosensor technology,” Measurement
Science and Technology, vol. 15, no. 2, pp. R1–R11, 2004.
[45] F. Lucarelli, L. Authier, G. Bagni, et al., “DNA biosensor inves-
tigationsinﬁshbileforuseasabiomonitoringtool,”Analytical
Letters, vol. 36, no. 9, pp. 1887–1901, 2003.
[ 4 6 ]J .W a n g ,G .R i v a s ,D .L u o ,X .C a i ,F .S .V a l e r a ,a n dN .D o n -
tha, “DNA-modiﬁed electrode for the detection of aromatic
amines,” Analytical Chemistry, vol. 68, no. 24, pp. 4365–4369,
1996.
[47] J .W ang,J .M.Chicarro,G.Rivas,etal.,“DN Abiosensorforthe
detection of hydrazines,” Analytical Chemistry, vol. 68, no. 13,
pp. 2251–2254, 1996.
[48] G.Chiti,G.Marrazza,andM.Mascini,“ElectrochemicalDNA
biosensor for environmental monitoring,” Analytica Chimica
Acta, vol. 427, no. 2, pp. 155–164, 2001.
[49] A. Erdem and M. Ozsoz, “Interaction of the anticancer drug
epirubicin with DNA,” Analytica Chimica Acta, vol. 437, no. 1,
pp. 107–114, 2001.
[ 5 0 ]F .L u c a r e l l i ,A .K i c e l a ,I .P a l c h e t t i ,G .M a r r a z z a ,a n dM .
Mascini, “Electrochemical DNA biosensor for analysis of
wastewater samples,” Bioelectrochemistry,v o l .5 8 ,n o .1 ,p p .
113–118, 2002.
[51] F. Lucarelli, I. Palchetti, G. Marrazza, and M. Mascini, “Elec-
trochemical DNA biosensor as a screening tool for the detec-
tion of toxicants in water and wastewater samples,” Talanta,
vol. 56, no. 5, pp. 949–957, 2002.
[52] V. C. Diculescu, A.- M. C. Paquim, and A. M. O. Brett, “Elec-
trochemical DNA sensors for detection of DNA damage,” Sen-
sors, vol. 5, no. 6–10, pp. 377–393, 2005.
[53] J. Labuda, K. Bubnicova, L. Kovalova, M. Vanickova, J. Mat-
tusch, and R. Wennrich, “Voltammetric detection of damage
to DNA by arsenic compounds at a DNA biosensor,” Sensors,
vol. 5, no. 6–10, pp. 411–423, 2005.
[54] G. Bagni, D. Osella, E. Sturchio, and M. Mascini, “Deoxyri-
bonucleic acid (DNA) biosensors for environmental risk as-
sessment and drug studies,” Analytica Chimica Acta, vol. 573-
574, pp. 81–89, 2006.
[55] G. Marrazza, G. Chiti, M. Mascini, and M. Anichini, “De-
tection of human apolipoprotein E genotypes by DNA elec-
trochemical biosensor coupled with PCR,” Clinical Chemistry,
vol. 46, no. 1, pp. 31–37, 2000.
[56] C.A.RabikandM.E.Dolan,“Molecularmechanismsofresis-
tance and toxicity associated with platinating agents,” Cancer
Treatment Reviews, vol. 33, no. 1, pp. 9–23, 2007.
[57] V. Brabec and J. Kasparkova, “Modiﬁcations of DNA by plat-
inum complexes: relation to resistance of tumors to platinum
antitumor drugs,” Drug Resistance Updates,v o l .8 ,n o .3 ,p p .
131–146, 2005.
[58] A. Cagnini, I. Palchetti, I. Lionti, M. Mascini, and A. P. F.
Turner, “Disposable ruthenized screen-printed biosensors for
pesticides monitoring,” Sensors and Actuators B,v o l .2 4 ,n o .1 –
3, pp. 85–89, 1995.
[59] G. Bagni, M. Ravera, D. Osella, and M. Mascini, “Electro-
chemical biosensors as a screening tool of in vitro DNA-drug
interaction,” CurrentPharmaceuticalAnalysis,v o l .1 ,n o .3 ,p p .
217–224, 2005.
[60] G. Bagni, DNA biosensors for environmental risk assessment
anddrugstudies,Ph.D.thesis,UniversityofFlorence,Florence,
Italy, 2005.
[61] M. L. Pedano and G. A. Rivas, “Immobilization of DNA
on glassy carbon electrodes for the development of aﬃnity
biosensors,” Biosensors and Bioelectronics,v o l .1 8 ,n o .2 ,p p .
269–277, 2003.
[62] V. Cai, G. Rivas, P. A. M. Farias, H. Shiraishi, J. Wang, and E.
Paleˇ cek, “Evaluation of diﬀerent carbon electrodes for adsorp-
tive stripping analysis of nucleic acids,” Electroanalysis, vol. 8,
no. 8-9, pp. 753–758, 1996.
[63] C. Xia, G. Shen, J. Jiang, and R. Yu, “Intercalation of phar-
morubicin anticancer drug to DNA studied by cyclic voltam-
metry with analytical applications,” Analytical letters, vol. 32,
no. 4, pp. 717–727, 1999.
[64] M. Ravera, S. Baracco, C. Cassino, et al., “Electrochemical
measurements conﬁrm the preferential bonding of the an-
timetastaticcomplex[ImH][RuC14 (DMSO)(Im)](NAMI-A)
with the proteins and the weak interaction with nucleobases,”
Inorganic Biochemistry, vol. 98, pp. 984–990, 2004.
[65] M. Mascini, G. Bangi, M. L. Di Pietro, M. Ravera, S. Baracco,
and D. Osella, “Electrochemical biosensor evaluation of the
interaction between DNA and metallo-drugs,” Biometals,
vol. 19, no. 4, pp. 409–418, 2006.
[66] S. J. Berners-Price and T. G. Appleton, “The chemistry of cis-
platin in aqueous solution,” in Platinum-Based Drugs in Can-
cer Therapy,L .R .K e l l a n d ,E d . ,p p .3 – 3 5 ,H u m a n aP r e s s ,T o -
towa, NJ, USA, 2000.
[67] P. M. Takahara, C. A. Frederick, and S. J. Lippard, “Crystal
structure of the anticancer drug cisplatin bound to duplex
DNA,” The American Chemical Society, vol. 118, no. 49, pp.
12309–12321, 1996.
[68] P. M. Takahara, A. C. Rosenzweig, C. A. Frederick, and
S. J. Lippard, “Crystal structure of double-stranded DNAMauro Ravera et al. 11
containing the major adduct of the anticancer drug cisplatin,”
Nature, vol. 377, no. 6550, pp. 649–652, 1995.
[69] A. P. Silverman, W. Bu, S. M. Cohen, and S. J. Lippard,
“2.4-˚ A crystal structure of the asymmetric platinum complex
{Pt(ammine)(cyclohexylamine)}
2+ bound to a dodecamer
DNA duplex,” The Journal of Biological Chemistry, vol. 277,
no. 51, pp. 49743–49749, 2002.
[70] M. A. Jakupec, M. Galanski, and B. K. Keppler, “Tumour-
inhibiting platinum complexes-state of the art and future per-
spectives,” Reviews of Physiology Biochemistry and Pharmacol-
ogy, vol. 146, pp. 1–53, 2003.
[71] W. Fery, J. D. Ranford, and P. J. Sadler, “Ring opening reac-
tions of the anticancer drug carboplatin: NMR characteriza-
tion of cis-[Pt(NH3)2(CBDCA-O)(5
 GMP-N7)] in solution,”
Inorganic Chemistry, vol. 32, pp. 1333–1340, 1993.
[72] M. Cusumano, M. L. Di Pietro, and A. Giannetto, “Rela-
tionship between binding aﬃnity for calf-thymus DNA of
[Pt(2,2
 
−bpy)(n −Rpy)2]
2+
(n = 2,4)andbasicityofcoordi-
nated pyridine,” Chemical Communications, no. 22, pp. 2527–
2528, 1996.
[73] D. P. Bancroft, C. A. Lepre, and S. J. Lippard, “Pt-195 NMR
kineticsandmechanisticstudiesofcis-diamminedichloroplat-
inum and trans-diamminedichloroplatinum(II) binding to
DNA,” Journal of the American Chemical Society, vol. 112, pp.
6860–6871, 1990.
[74] O.Heudi,S.Mercier-Jobard,A.Cailleux,andP.Allain,“Mech-
anisms of reaction of L-methionine with carboplatin and ox-
aliplatin in diﬀerent media: a comparison with cisplatin,” Bio-
pharmaceutics and Drug Disposition, vol. 20, no. 2, pp. 107–
116, 1999.
[75] J. Malina, O. Novakova, B. K. Keppler, E. Alessio, and V.
Brabec, “Biophysical analysis of natural, double-helical DNA
modiﬁed by anticancer heterocyclic complexes of ruthe-
nium(III) in cell-free media,” Journal of Biological Inorganic
Chemistry, vol. 6, no. 4, pp. 435–445, 2001.
[ 7 6 ]E .G a l l o r i ,C .V e t t o r i ,E .A l e s s i o ,e ta l . ,“ D N Aa sap o s s i -
ble target for antitumor ruthenium(III) complexes: a spectro-
scopic and molecular biology study of the interactions of two
representative antineoplastic ruthenium(III) complexes with
DNA,” Archives of Biochemistry and Biophysics, vol. 376, no. 1,
pp. 156–162, 2000.
[ 7 7 ]L .M e s s o r i ,P .O r i o l i ,D .V u l l o ,E .A l e s s i o ,a n dE .I e n g o ,“ A
spectroscopic study of the reaction of NAMI, a novel ruthe-
nium(III) anti-neoplastic complex, with bovine serum albu-
min,” European Journal of Biochemistry, vol. 267, no. 4, pp.
1206–1213, 2000.
[ 7 8 ]A .R .T i m e r b a e v ,C .G .H a r t i n g e r ,S .S .A l e k s e n k o ,a n dB .K .
Keppler, “Interactions of antitumor metallodrugs with serum
proteins: advances in characterization using modern analyti-
cal methodology,” Chemical Reviews, vol. 106, no. 6, pp. 2224–
2248, 2006.
[79] G. Sava, E. Alessio, A. Bergamo, and G. Mestroni, “Sulfoxide
ruthenium complexes: non-toxic tools for the selective treat-
ment of solid tumour metastases,” in Topics in Biological Inor-
ganic Chemistry, Vol. 1: Metallopharmaceuticals I DNA Interac-
tions, pp. 144–169, Springer, Berlin, Germany, 1999.
[80] L. Y. Kuo, A. H. Liu, and T. J. Marks, “Metallocene interac-
tions with DNA and DNA-processing enzymes,” Metal Ions in
Biological Systems, vol. 33, pp. 53–85, 1996.
[81] G. Mokdsi and M. M. Harding, “Water soluble, hydrolyt-
ically stable derivatives of the antitumor drug titanocene
dichloride and binding studies with nucleotides,” Journal of
Organometallic Chemistry, vol. 565, no. 1-2, pp. 29–35, 1998.
[82] M. M. Harding, G. Mokdsi, J. P. Mackay, M. Prodigalidad,
and S. W. Lucas, “Interactions of the antitumor agent molyb-
docene dichloride with oligonucleotides,” Inorganic Chem-
istry, vol. 37, no. 10, pp. 2432–2437, 1998.
[83] P. K¨ opf-Maier, “Intracellular localization of titanium within
xenografted sensitive human tumors after treatment with the
antitumor agent titanocene dichloride,” Journal of Structural
Biology, vol. 105, no. 1–3, pp. 35–45, 1990.
[84] M. Guo, Z. Guo, and P. Sadler, “Titanium(IV) targets phos-
phoesters on nucleotides: implications for the mechanism of
action of the anticancer drug titanocene dichloride,” Journal
of Biological Inorganic Chemistry, vol. 6, no. 7, pp. 698–707,
2001.
[85] L. A. Zwelling, T. Anderson, and K. W. Kohn, “DNA-protein
and DNA interstrand cross-linking by cis-a n dt r a n s p l a t -
inum(II) diamminedichloride in L1210 mouse leukemia cells
and relation to cytotoxicity,” Cancer Research, vol. 39, no. 2,
part 1, pp. 365–369, 1979.
[ 8 6 ] R .J .K n o x ,F .F r i e d l o s ,D .A .L y d a l l ,a n dJ .J .R o b e r t s ,“ M e c h a -
nism of cytotoxicity of anticancer platinum drugs: evidence
that cis-diamminedichloroplatinum(II) and cis-diammine-
(1,1-cyclobutanedicarboxylato)platinum(II) diﬀer only in the
kinetics of their interaction with DNA,” Cancer Research,
vol. 46, no. 4, part 2, pp. 1972–1979, 1986.
[87] E. Lindauer and E. Holler, “Cellular distribution and cellular
reactivity of platinum(II) complexes,” Biochemical Pharmacol-
ogy, vol. 52, no. 1, pp. 7–14, 1996.
[88] M. F. Pera Jr., C. J. Rawlings, and J. J. Roberts, “The role of
D N Ar e p a i ri nt h er e c o v e ryo fh u m a nc e l l sf r o mc i s p l a t i nt o x i -
city,” Chemico-Biological Interactions, vol. 37, no. 1-2, pp. 245–
261, 1981.
[89] A. B. Steel, T. M. Herne, and M. J. Tarlov, “Electrochemical
quantitation of DNA immobilized on gold,” Analytical Chem-
istry, vol. 70, no. 22, pp. 4670–4677, 1998.